Involvement of Mast Cells in the Pathology of COVID-19: Clinical and Laboratory Parallels
Author:
Budnevsky Andrey V.1ORCID, Avdeev Sergey N.2ORCID, Kosanovic Djuro2, Ovsyannikov Evgeniy S.1ORCID, Savushkina Inessa A.1ORCID, Alekseeva Nadezhda G.1, Feigelman Sofia N.1ORCID, Shishkina Viktoria V.13ORCID, Filin Andrey A.13ORCID, Esaulenko Dmitry I.3, Perveeva Inna M.4
Affiliation:
1. Department of Faculty Therapy, Voronezh State Medical University Named after N.N. Burdenko, Studencheskaya Street 10, 394622 Voronezh, Russia 2. Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Street 8, 119991 Moscow, Russia 3. Research Institute of Experimental Biology and Medicine, Voronezh State Medical University Named after N.N. Burdenko, Moskovskiy Avenue, 185, 394066 Voronezh, Russia 4. Voronezh Regional Clinical Hospital No. 1, Moskovskiy Avenue, 151, 394066 Voronezh, Russia
Abstract
Recent studies suggested the potential role of mast cells (MCs) in the pathology of coronavirus disease 2019 (COVID-19). However, the precise description of the MCs’ activation and the engagement of their proteases is still missing. The objective of this study was to further reveal the importance of MCs and their proteases (chymase, tryptase, and carboxypeptidase A3 (CPA3)) in the development of lung damage in patients with COVID-19. This study included 55 patients who died from COVID-19 and 30 controls who died from external causes. A histological analysis of the lung parenchyma was carried out to assess the protease profiles and degranulation activity of MCs. In addition, we have analyzed the general blood test, coagulogram, and C-reactive protein. The content of tryptase-positive MCs (Try-MCs) in the lungs of patients with COVID-19 was higher than in controls, but their degranulation activity was lower. The indicators of chymase-positive MCs (Chy-MCs) were significantly lower than in the controls, while the content of CPA3-positive MCs (CPA3-MCs) and their degranulation activity were higher in patients with COVID-19. In addition, we have demonstrated the existence of correlations (positive/negative) between the content of Try-MCs, Chy-MCs, and CPA3-MCs at different states of their degranulation and presence (co-adjacent/single) and the levels of various immune cells (neutrophils, eosinophils, basophils, and monocytes) and other important markers (blood hemoglobin, activated partial thromboplastin time (aPTT), international normalized ratio (INR), and fibrinogen). Thus, the identified patterns suggest the numerous and diverse mechanisms of the participation of MCs and their proteases in the pathogenesis of COVID-19, and their impact on the inflammatory process and coagulation status. At the same time, the issue requires further study in larger cohorts of patients, which will open up the possibility of using drugs acting on this link of pathogenesis to treat lung damage in patients with COVID-19.
Reference29 articles.
1. (2023, November 02). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/#:~:text=Globally%2C%20as%20of%205%3A57pm%20CEST%2C,6%2C974%2C473%20deaths%2C%20reported%20to%20WHO. 2. Zanza, C., Romenskaya, T., Manetti, A.C., Franceschi, F., La Russa, R., Bertozzi, G., Maiese, A., Savioli, G., Volonnino, G., and Longhitano, Y. (2022). Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. Medicina, 58. 3. Innate immunity, cytokine storm, and inflammatory cell death in COVID-19;Karki;J. Transl. Med.,2022 4. Brock, I., and Maitland, A. (2021). Mast Cells and COVID-19: A case report implicating a role of mast cell activation in the prevention and treatment of COVID-19. J. Vaccines Vaccin., 36–39. 5. Cytokine storm. Causes and consequences;Potapnev;Immunol.-Immunol.,2021
|
|